New Stock News | Acrobiosystems (301080.SZ) Files Again with the Hong Kong Stock Exchange, Ranked Third Among Suppliers in China's Biological Reagent Industry

According to a disclosure by the Hong Kong Stock Exchange on September 30, Beijing Acrobiosystems Biotechnology Co., Ltd. (referred to as: Acrobiosystems, 301080.SZ) has once again submitted a listing application to the Main Board of the Hong Kong Stock Exchange, with CMSC International acting as its sole sponsor. Company Overview According to the prospectus, the company is primarily engaged in the research and development, production, and sales of recombinant proteins, antibodies, and assay kits. According to Frost & Sullivan, the company occupies a favorable position in the biological reagent industry, particularly in the recombinant protein segment. Based on 2025 revenue, the company ranks first among all Chinese suppliers in the global recombinant protein market and third among all suppliers, with a global market share of 2.7%, while the top two market participants collectively hold a 33.0% market share. Based on 2025 revenue, the company ranks third among all suppliers in China's biological reagent industry, with a market share of 2.6%, while the top two market participants collectively hold a 17.6% market share. Notably, according to Frost & Sullivan, from 2023 to 2025, compared with the top five participants in the global biological reagent market (by revenue), the company achieved a higher revenue growth rate. The company offers a comprehensive product portfolio that integrates biological reagents (including recombinant proteins, antibodies, assay kits, and other products), supplemented by a range of technical services. The synergies among the company's products enable it to provide customized solutions that meet the critical needs of biopharmaceutical R&D from early target discovery to clinical trials. Specifically: (i) vertically, the company's product portfolio covers the tool chain from target discovery, drug screening and optimization to preclinical research, ensuring experimental continuity and consistent, comparable data; (ii) horizontally, the company deeply integrates reagent products such as recombinant proteins with technical capabilities to address key industry R&D bottlenecks, such as the expression of difficult-to-express proteins; and (iii) by leveraging the synergies between products and data across preclinical and clinical trial stages, the company achieves full traceability of research results and maintains dataset consistency. As of the Latest Practicable Date, the company offers more than 5,000 SKUs of products and various technical services, all of which are manufactured or provided in accordance with applicable international and industry-recognized quality standards and frameworks, including ISO 9001:2015, ISO 13485:2016, current Good Manufacturing Practice, the Medical Device Single Audit Program (MDSAP), and Rx-360. The company serves a diverse customer base, including leading global pharmaceutical companies and biotechnology companies. The company's solutions cover multiple therapeutic areas, such as oncology, autoimmune diseases, cardiovascular diseases, metabolic diseases, central nervous system disorders, and infectious diseases, while actively supporting modalities including conjugated drugs (XDC), ADCs, cell and gene therapy (CGT), and multi-specific antibodies. Financial Information Revenue For the years 2023, 2024, 2025, and the seven months ended July 31, 2026, the company's revenue was approximately RMB 544 million, RMB 645 million, RMB 838 million, and RMB 606 million, respectively. Profit For the years 2023, 2024, 2025, and the seven months ended July 31, 2026, the company's annual/period profit was approximately RMB 148 million, RMB 120 million, RMB 165 million, and RMB 123 million, respectively. Industry Overview In 2020, the global and Chinese biological reagent markets reached USD 18.2 billion and USD 2.2 billion, respectively, growing at compound annual growth rates of 7.7% and 16.2% to reach USD 26.4 billion and USD 4.6 billion by 2025. It is expected that by 2032, these markets will further expand to USD 39.5 billion and USD 13.4 billion, with compound annual growth rates of 5.9% and 16.8% from 2025 to 2032, respectively. Biological reagents can be divided into three types, namely cell-based, protein-based, and nucleic acid-based. Protein-based reagents are further divided into antibodies, recombinant proteins, and others. In 2025, by revenue, the protein-based biological reagent segment accounted for 36.3% of the total global biological reagent market. In 2025, by revenue, the global recombinant protein segment accounted for 36.0% of the total global protein-based biological reagent market and is expected to increase to 51.0% by 2032. In 2025, recombinant protein reagents accounted for 13.1% of the global biological reagent market, making them a key growth engine for the industry. Looking ahead, recombinant proteins are expected to continue increasing their share of protein-based reagents and record the fastest growth among all protein-based reagent categories. The growth in the share of recombinant protein reagents is primarily driven by technological advancements, which have significantly increased the usage of certain reagents, including enzymes and diagnostic raw materials. In 2020, the global and Chinese recombinant protein markets reached USD 1 billion and USD 100 million, respectively, reaching USD 3.5 billion and USD 400 million by 2025 at compound annual growth rates of 28.2% and 25.2%, respectively. These markets are projected to further expand to USD 8.6 billion and USD 1.3 billion by 2032, with compound annual growth rates of 14.0% and 17.0% from 2025 to 2032, respectively. Driven by factors such as rising healthcare demand and increasingly comprehensive regulatory frameworks, from 2020 to 2030, the compound annual growth rate of the biopharmaceutical market was significantly higher than the average growth rate of the overall pharmaceutical market. In 2025, the global biologics market reached USD 474.9 billion and is expected to reach USD 911.0 billion by 2032, with a compound annual growth rate of 9.8%. By comparison, benefiting from improved medical reimbursement capabilities and an expanding patient population, China's biologics market reached RMB 523.9 billion in 2025. It is expected that by 2032, the Chinese market will further grow to RMB 1,275.3 billion, with a compound annual growth rate of 13.6%. Board of Directors Information The company's board of directors is responsible for managing and operating the company's business and has general powers in this regard. The company's board of directors consists of seven directors, including three executive directors, one non-executive director, and three independent non-executive directors. Shareholding Structure Pursuant to the concert party agreement and Mr. Chen's identity as the general partner of Anyi Acrobiosystems and Anyi Baipu Jiale, Mr. Chen, Mr. Miao, Anyi Acrobiosystems, and Anyi Baipu Jiale collectively constitute the company's controlling shareholder group, exercising approximately 41.36% of the company's total voting rights as of the Latest Practicable Date. Intermediary Team Sole Sponsor: CMSC (Hong Kong) Limited; Legal Advisors: Morgan, Lewis & Bockius, Ms. Wu Wing Shan, Llinks Law Offices, etc.; Legal Advisors to the Sole Sponsor: Fangda Partners, King & Wood Mallesons; Auditors and Reporting Accountants: Rongcheng (Hong Kong) CPA Limited; Independent Industry Advisor: Frost & Sullivan (Beijing) Consulting Co., Ltd. Shanghai Branch; Transfer Pricing Advisor: Ernst & Young (China) Enterprise Consulting Co., Ltd. Beijing Branch; Compliance Advisor: Alliance Capital Partners Limited.